Recurrence of metastatic Merkel carcinoma after cessation of avelumab in a patient previously with a complete response

Autor: Alexandra Picard‐Gauci, Laura Troin, Madleen Chassang, Thierry Passeron, Henri Montaudié

Publikováno v: JEADV Clinical Practice, Vol 1, Iss 2, Pp 129-131 (2022)

Abstract Background Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine malignancy. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with metastatic MCC (mMCC). In mMCC, the response

Externí odkaz: https://doaj.org/article/edcacaa87e3043dcbf2642351ca2e95e

ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Autor: Yann Cheli, Meri K. Tulic, Najla El Hachem, Nicolas Nottet, Arnaud Jacquel, Maeva Gesson, Thomas Strub, Karine Bille, Alexandra Picard-Gauci, Henri Montaudié, Guillaume E. Beranger, Thierry Passeron, Pierre Close, Corine Bertolotto, Robert Ballotti

Publikováno v: Molecular Cancer, Vol 20, Iss 1, Pp 1-5 (2021)

Abstract Resistances to immunotherapies remains a major hurdle towards a cure for melanoma in numerous patients. An increase in the mesenchymal phenotype and a loss of differentiation have been clearly associated with resistance to targeted therapies

Externí odkaz: https://doaj.org/article/a109a58f73fa4ac585009c1946fc3fba

Loss of LYN Is Frequent in Targeted Therapy-Resistant Melanoma Cells and Favors Metastatic Properties.

Autor: Gaudel C; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Pisibon C; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France; Equipe labellisée ARC 2022, Nice, France., Soysouvanh F; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Giuliano S; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France; Equipe labellisée ARC 2022, Nice, France., Picard-Gauci A; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France; Département de Dermatologie, CHU de Nice, Nice, France., Leclerc J; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France., Hofman P; Université Côte d'Azur, Nice, France; Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, IHU RespirERA, Nice, France., Bahadoran P; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France; Equipe labellisée ARC 2022, Nice, France; Département de Dermatologie, CHU de Nice, Nice, France., Bertolotto C; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France; Equipe labellisée Ligue Contre le Cancer 2020, Nice, France., Ballotti R; Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France; Equipe labellisée ARC 2022, Nice, France. Electronic address: ballotti@unice.fr.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2025 Jan; Vol. 145 (1), pp. 214-218.e5. Date of Electronic Publication: 2024 Jul 20.

Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma

Autor: Marius Ilié, Elisabeth Lantéri, Emmanuel Chamorey, Brice Thamphya, Marame Hamila, Henri Montaudié, Alexandra Picard-Gauci, Sophie Gardrat, Thierry Passeron, Sandra Lassalle, Elodie Long-Mira, Julien Cherfils-Vicini, Eric Gilson, Véronique Hofman, Paul Hofman

Publikováno v: OncoImmunology, Vol 10, Iss 1 (2021)

The outcome of patients with cutaneous melanoma has been strongly modified by recent advances obtained with Immune Checkpoint Inhibitors (ICIs). However, despite this breakthrough, durable response to ICIs is limited to a subset of patients. We inves

Externí odkaz: https://doaj.org/article/bfd4f825455c4ae1a40fb600d495b127

Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes

Autor: Elodie Long-Mira, Alexandra Picard-Gauci, Sandra Lassalle, Véronique Hofman, Salomé Lalvée, Virginie Tanga, Katia Zahaf, Christelle Bonnetaud, Virginie Lespinet, Olivier Camuzard, Henri Montaudié, Gilles Poissonnet, Thierry Passeron, Marius Ilié, Paul Hofman

Publikováno v: Diagnostics, Vol 12, Iss 3, p 751 (2022)

Testing for the BRAF mutation is mandatory for the management of patients with locally advanced or metastatic melanoma. Molecular analysis based on DNA sequencing remains the gold-standard method for the screening of the different BRAF mutations. The

Externí odkaz: https://doaj.org/article/c45daa640a564eeda293675f6eb69b78